Why the Paradigm (ASX:PAR) share price is lifting today

The company is making progress on its study.
The post Why the Paradigm (ASX:PAR) share price is lifting today appeared first on The Motley Fool Australia. –

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is on the move this Friday. This comes after the biopharmaceutical company provided an update in regards to its upcoming clinical trial.

At the time of writing, Paradigm’s shares are fetching for $2.12, up 3.41%.

What did Paradigm announce?

In today’s statement, Paradigm advised it has received an Australian ethics approval for its pivotal phase 3 clinical trial, PARA_OA_002.

The study will see the treatment of pentosan polysulfate sodium (PPS) against placebo on participants with Knee Osteoarthritis Pain.

PPS, an injectable solution, aims to treat musculoskeletal disorders caused by injury, inflammation, aging, degenerative disease, infection or genetic predisposition. The semi-synthetic drug is packaged as Zilosul and has shown improvements in pain reduction, joint function, and the prevention of cartilage damaging joints.

Evaluation will be done through WOMAC pain and WOMAC function at multiple time points from day 1 to day 168.

WOMAC is a widely-used health tool that assesses physical function, pain, and stiffness in patients with Osteoarthritis. The self-administered instrument gives a score range for each of the three subclasses to indicate the patient’s health status.

Paradigm is eyeing 8 sites across 5 states in Australia to conduct its PARA_OA_002 study. The states include Victoria, Western Australia, Queensland, South Australia and New South Wales.

Patient recruitment and screening are set to commence during the fourth quarter of the calendar year.

In addition, the company expects to receive a response this month from the United States Food and Drug Administration. This is in relation to its Investigational New Drug (IND) application to begin the United States arm of the study.

Management commentary

Paradigm CEO, Paul Rennie said:

We are pleased to report that preparations to commence our Phase 3 clinical trial are progressing whilst we await the US FDA’s response, expected at the end of September. We expect that, in addition to the 8 Australian sites, there will be clinical sites in UK and Europe and, subject to the FDA’s response, in the US. Our preparation to expand into these additional sites is well underway. Commencing the Phase 3 clinical study is a significant milestone for the Company.

Paradigm share price snapshot

The Paradigm share price has been up and down over the past 12 months, reaching as high as $3.19 and as low as $1.76. While losing around 10% in value since this time last year, its shares are down further by 20% in 2021.

Paradigm commands a market capitalisation of roughly $465.82 million and has approximately 229.91 million shares on its registry.

The post Why the Paradigm (ASX:PAR) share price is lifting today appeared first on The Motley Fool Australia.

Should you invest $1,000 in Paradigm right now?

Before you consider Paradigm, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Paradigm wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Why the Flight Centre (ASX:FLT) share price reached a new 52-week high today
Why the Centuria Industrial (ASX:CIP) share price is down 8% today
3 more small-cap ASX shares with a competitive edge

Why the 92 Energy (ASX:92E) share price is frozen today
Vulcan (ASX:VUL) share price edges lower on share purchase plan update

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!